Persistent behavioral impairments and alterations of brain dopamine system after early postnatal administration of thimerosal in rats

Behavioural Brain Research

Volumn 223, Issue 1, 2011, Pages 107-118

  Olczak, Mieszko ^a,c   Duszczyk, Michalina ^a   Mierzejewski, Pawel ^a   Meyza, Ksenia ^b   Majewska, Maria Dorota ^a,d  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d CARDINAL STEFAN WYSZY SKI UNIVERSITY   (Poland)

Author keywords

Behavior; Dopamine; Impairment; Neurodevelopment; Rat; Thimerosal

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; THIOMERSAL;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTISOCIAL BEHAVIOR; ANXIETY; ARTICLE; AUTISM; BEHAVIOR DISORDER; CATALEPSY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG EXPOSURE; FEMALE; LEARNING; LOCOMOTION; MALE; MEMORY; NEUROTOXICITY; NEWBORN; NONHUMAN; PERINATAL PERIOD; PHOBIA; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; SOCIAL INTERACTION; SPATIAL LEARNING;

ANIMALS; CATALEPSY; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; FEMALE; HALOPERIDOL; MALE; MAZE LEARNING; MERCURY POISONING, NERVOUS SYSTEM; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SEX CHARACTERISTICS; SOCIAL BEHAVIOR; THIMEROSAL;

EID: 79955965445     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.04.026     Document Type: Article

References (63)

1. Qvarnström J., Lambertsson L., Havarinasab S., Hultman P., Frech W. Determination of methylmercury, ethylmercury, and inorganic mercury in mouse tissues, following administration of thimerosal, by species-specific isotope dilution GC-inductively coupled plasma-MS. Anal Chem 2003, 75:4120-4124.
2. Burbacher T.M., Shen D.D., Liberato N., Grant K.S., Cernichiari E., Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect 2005, 113:1015-1021.
3. Redwood L., Bernard S., Brown D. Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology 2001, 22:691-697.
4. Geier D.A., Geier M.R. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006, 27:401-413.
5. Geier D.A., Kern J.K., Geier M.R. The biological basis of autism spectrum disorders: understanding causation and treatment by clinical geneticists. Acta Neurobiol Exp (Wars) 2010, 70:209-226.
6. Mutter J., Naumann J., Schneider R., Walach H., Haley B. Mercury and autism: accelerating evidence?. Neuro Endocrinol Lett 2005, 26:439-446.
7. Gallagher C., Goodman M. Hepatitis B triple series vaccine and developmental disability in US children aged 1-9 years. Toxicol Environ Chem 2008, 90:997-1008.
8. Dórea J.G. Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines. Neurochem Res 2011, February 25 [Epub ahead of print].
9. Majewska M.D., Urbanowicz E., Rok-Bujko P., Namyslowska I., Mierzejewski P. Age-dependent lower or higher levels of hair mercury in autistic children than in healthy controls. Acta Neurobiol Exp (Wars) 2010, 70:196-208.
10. Baskin D.S., Ngo H., Didenko V.V. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci 2003, 74:361-368.
11. Yel L., Brown L.E., Su K., Gollapudi S., Gupta S. Thimerosal induces neuronal cell apoptosis by causing cytochrome c and apoptosis-inducing factor release from mitochondria. Int J Mol Med 2005, 16:971-977.
12. Humphrey M.L., Cole M.P., Pendergrass J.C., Kiningham K.K. Mitochondrial mediated thimerosal-induced apoptosis in a human neuroblastoma cell line (SK-N-SH). Neurotoxicology 2005, 26:407-416.
13. Herdman M.L., Marcelo A., Huang Y., Niles R.M., Dhar S., Kiningham K.K. Thimerosal induces apoptosis in a neuroblastoma model via the cJun N-terminal kinase pathway. Toxicol Sci 2006, 92:246-253.
14. Olczak M., Duszczyk M., Mierzejewski P., Wierzba-Bobrowicz T., Majewska M.D. Lasting neuropathological changes in rat brain after intermittent neonatal administration of thimerosal. Folia Neuropathol 2010, 48:258-269.
15. Zieminska E., Toczylowska B., Stafiej A., Lazarewicz J.W. Low molecular weight thiols reduce thimerosal neurotoxicity in vitro: modulation by proteins. Toxicology 2010, 276:154-163.
16. Parran D.K., Barker A., Ehrich M. Effects of thimerosal on NGF signal transduction and cell death in neuroblastoma cells. Toxicol Sci 2005, 86:132-140.
17. James S.J., Slikker W., Melnyk S., New E., Pogribna M., Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005, 26:1-8.
18. Minami T., Miyata E., Sakamoto Y., Kohama A., Yamazaki H., Ichida S. Expression of metallothionein mRNAs on mouse cerebellum microglia cells by thimerosal and its metabolites. Toxicology 2009, 261:25-32.
19. Clarkson T.W. Metal toxicity in the central nervous system. Environ Health Perspect 1987, 75:59-64.
20. Haley B.E. Mercury toxicity: genetic susceptibility and synergistic effects. Med Veritas 2005, 2:535-542.
21. Prandota J. Autism spectrum disorders may be due to cerebral toxoplasmosis associated with chronic neuroinflammation causing persistent hypercytokinemia that resulted in increased lipid peroxidation, oxidative stress, and depressed metabolism of endogenous and exogenous substances. Res Autism Spectr Disord 2010, 4:119-155.
22. Abedi-Valugerdi M., Nilsson C., Zargari A., Gharibdoost F., DePierre J.W., Hassan M. Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice. Clin Exp Immunol 2005, 141:238-247.
23. Hornig M., Chian D., Lipkin W.I. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry 2004, 9:833-845.
24. Laurente J., Remuzgo F., Ávalos B., Chiquinta J., Ponce B., Avendaño R., et al. Neurotoxic effects of thimerosal at vaccines doses on the encephalon and development in 7 days-old hamsters. Ann Fac Med Lima 2007, 68:222-237.
25. Hewitson L., Houser L.A., Stott C., Sackett G., Tomko J.L., Atwood D., et al. Delayed acquisition of neonatal reflexes in newborn primates receiving a thimerosal-containing hepatitis B vaccine: influence of gestational age and birth weight. J Toxicol Environ Health A 2010, 73:1298-1313.
26. Hewitson L., Lopresti B.J., Stott C., Mason N.S., Tomko J. Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: a pilot study. Acta Neurobiol Exp (Wars) 2010, 70:147-164.
27. Berman R.F., Pessah I.N., Mouton P.R., Mav D., Harry J. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice. Toxicol Sci 2008, 101:294-309.
28. Olczak M., Duszczyk M., Mierzejewski P., Majewska M.D. Neonatal administration of a vaccine preservative, thimerosal, produces lasting impairment of nociception and apparent activation of opioid system in rats. Brain Res 2009, 1301:143-151.
29. Olczak M., Duszczyk M., Mierzejewski P., Bobrowicz T., Majewska M.D. Neonatal administration of thimerosal causes persistent changes in mu opioid receptors in the rat brain. Neurochem Res 2010, 35:1840-1847.
30. Green D., Charman T., Pickles A., Chandler S., Loucas T., Simonoff E., et al. Impairment in movement skills of children with autistic spectrum disorders. Dev Med Child Neurol 2009, 51:311-316.
31. Staples K.L., Reid G. Fundamental movement skills and autism spectrum disorders. J Autism Dev Disord 2010, 40:209-217.
32. Gjevik E., Eldevik S., Fjæran-Granum T., Sponheim E. Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders. J Autism Dev Disord 2010, September 8 [Epub ahead of print].
33. Schreibman L. Diagnostic features of autism. J Child Neurol 1988, 3 Suppl.:S57-S64.
34. Tuchman R. Autism. Neurol Clin 2003, 21:915-932.
35. Gillberg C., Svennerholm L. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 1987, 151:89-94.
36. Garreau B., Barthélémy C., Jouve J., Bruneau N., Muh J.P., Lelord G. Urinary homovanillic acid levels of autistic children. Dev Med Child Neurol 1988, 30:93-98.
37. Salgado-Pineda P., Delaveau P., Blin O., Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol 2005, 28:228-237.
38. Arias-Carrión O., Pǒppel E. Dopamine, learning, and reward-seeking behavior. Acta Neurobiol Exp (Wars) 2007, 67:481-488.
39. Sanberg P.R. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 1980, 284:472-473.
40. Carlsson A. On the neuronal circuitries and neurotransmitters involved in the control of locomotor activity. J Neural Transm Suppl 1993, 40:1-12.
41. Groenewegen H.J. The basal ganglia and motor control. Neural Plast 2003, 10:107-120.
42. Heien M.L., Wightman R.M. Phasic dopamine signaling during behavior, reward, and disease states. CNS Neurol Disord Drug Targets 2006, 5:99-108.
43. Hauber W. Dopamine release in the prefrontal cortex and striatum: temporal and behavioural aspects. Pharmacopsychiatry 2010, 43 Suppl. 1:S32-S41.
44. Short protocols in neuroscience, systems and behavioral methods 2006, John Wiley and Sons Inc., Hoboken, NJ. J. Crawley, C. Gerfen, M. Rogawski, D. Sibley, P. Skolnick, S. Wray (Eds.).
45. Meyza K.Z., Boguszewski P.M., Nikolaev E., Zagrodzka J. Diverse sensitivity of RHA/Verh and RLA/Verh rats to emotional and spatial aspects of a novel environment as a result of a distinct pattern of neuronal activation in the fear/anxiety circuit. Behav Genet 2009, 39:48-61.
46. Rogowski A., Rokicki D., Kostowski W., Bienkowski P. Relationship between dopamine D2 receptor-associated responses and operant ethanol self-administration in the rat: a factor analysis. Alcohol Alcohol 2003, 38:305-309.
47. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press, Oxford, UK.
48. Anderson B.D., Nakamura T., Russell S.J., Peng K.W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004, 64:4919-4926.
49. Muraoka Y., Itoh F. Sex difference of mercuric chloride-induced renal tubular necrosis in rats-from the aspect of sex differences in renal mercury concentration and sulfhydryl levels. J Toxicol Sci 1980, 5:203-214.
50. Clarkson T.W., Nordberg G.F., Sager P.R. Reproductive and developmental toxicity of metals. Scand J Work Environ Health 1985, 11:145-154.
51. Branch D.R. Gender-selective toxicity of thimerosal. Exp Toxicol Pathol 2009, 61:133-136.
52. Ekstrand J., Nielsen J.B., Havarinasab S., Zalups R.K., Söderkvist P., Hultman P. Mercury toxicokinetics-dependency on strain and gender. Toxicol Appl Pharmacol 2010, 243:283-291.
53. Carvalho M.C., Franco J.L., Ghizoni H., Kobus K., Nazari E.M., Rocha J.B., et al. Effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) on methylmercury-induced locomotor deficits and cerebellar toxicity in mice. Toxicology 2007, 239:195-203.
54. Olczak M., Duszczyk M., Mierzejewski P., Wierzba-Bobrowicz T., Majewska M.D. Lasting neuropathological changes in rat brain after intermittent neonatal administration of thimerosal. Folia Neuropathologica 2010, 48:258-269.
55. Basu N., ScheuhammerAM, Rouvinen-Watt K., Evans R.D., Trudeau V.L., Chan L.H. In vitro and whole animal evidence that methylmercury disrupts GABAergic systems in discrete brain regions in captive mink. Comp Biochem Physiol C: Toxicol Pharmacol 2010, 151:379-385.
56. O'Kusky J.R., McGeer E.G. Methylmercury poisoning of the developing nervous system in the rat: decreased activity of glutamic acid decarboxylase in cerebral cortex and neostriatum. Brain Res 1985, 353:299-306.
57. Wyrembek P., Szczuraszek K., Majewska M.D., Mozrzymas J.W. Intermingled modulatory and neurotoxic effects of thimerosal and mercuric ions on electrophysiological responses to GABA and NMDA in hippocampal neurons. J Physiol Pharmacol 2010, 61:753-758.
58. Komulainen H., Tuomisto J. 3H-dopamine uptake and 3H-haloperidol binding in striatum after administration of methyl mercury to rats. Arch Toxicol 1985, 57:268-271.
59. Scheuhammer A.M., Cherian M.G. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors. Biochem Pharmacol 1985, 34:3405-3413.
60. Daré E., Fetissov S., Hökfelt T., Hall H., Ogren S.O., Ceccatelli S. Effects of prenatal exposure to methylmercury on dopamine-mediated locomotor activity and dopamine D2 receptor binding. Naunyn Schmiedebergs Arch Pharmacol 2003, 367:500-508.
61. Faro L.R., do Nascimento J.L., Alfonso M., Durán R. Mechanism of action of methylmercury on in vivo striatal dopamine release. Possible involvement of dopamine transporter. Neurochem Int 2002, 40:455-465.
62. Dreiem A., Shan M., Okoniewski R.J., Sanchez-Morrissey S., Seegal R.F. Methylmercury inhibits dopaminergic function in rat pup synaptosomes in an age-dependent manner. Neurotoxicol Teratol 2009, 31:312-317.
63. Kauer J.A., Malenka R.C., Nicoll R.A. A persistent postsynaptic modification mediates long-term potentiation in the hippocampus. Neuron 1988, 1:911-917.